1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020

Biological drugs are typically derived from living cells and are used in the prevention and treatment of various diseases such as cancer, blood disorders, auto-immune diseases and other medical conditions. Biological drugs have more complex structures compared to that of conventional drugs. These are highly sensitive and more difficult to characterize and develop. A biological drug typically has around 250 in-process tests during manufacturing compared to around 50 tests for a conventional drug.

The increasing prevalence of chronic diseases and growing geriatric population are the major drivers of the global biological drugs market. In addition, various government associations are also supporting the growth of the biological drugs market. Furthermore, advancements in biomedical science hold immense potential for the growth of the biological drugs market. However, high costs of biological drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, risks of adverse effects associated with biologic injectable drugs are also inhibiting the growth of the biological drugs market.

In terms of geography, North America dominates the global biological drugs market. This is due to increasing use of biological drugs for the treatment of diseases such as cancer, diabetes, and other chronic diseases. In addition, various government associations are promoting the usage of biological drugs in North America. For instance, in 2012, the American College of Rheumatology – an organization that advances rheumatology through education and research – recommended biologic agents and disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis.

In Europe, the biological drugs market is growing due to increasing aging population in the region. According to a UN report, elderly people accounted for 23.2% of the total population in Germany in 2000, and the number is expected to reach 33.2% by 2025. Aging can lead to certain disorders such as age-related macular degeneration and glaucoma, which require biological drugs for their effective treatment.

Low manufacturing costs in Asia attract biopharmaceutical companies to invest in the region. For instance, Lonza – a Switzerland-based biotechnology company – invested around US$ 350 Mn in Singapore and India, in order to encourage biological activities.

This report provides in-depth analysis and estimation of the biological drugs market for the period 2014–2020, considering 2014 as the base year for the calculation. In addition, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibodies (mAb), and vaccines. Based on therapeutic protein, the market segments include Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. Based on mAb, the report comprises Humira, Remicade, Rituxan, Avastin, Herceptin, and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax, and Cervarix. On the basis of geography, the report identifies and analyzes the market size and predictions for North America, Europe, Asia, and Rest of the World (RoW).

Some of the major players in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc., and Biogen Idec. These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Table Of Contents

Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020
Chapter 1 Preface 11

1.1 Report Description 11

1.2 Report Methodology 12

1.3 Assumptions 12

Chapter 2 Market Synopsis 13

Chapter 3 Porter's Five Forces Analysis 14

3.1 Bargaining power of suppliers 14

3.2 Bargaining power of buyers 15

3.3 Threat of new entrants 15

3.4 Threat of substitutes 15

3.5 Intensity of rivalry 15

Chapter 4 Industry Overview 17

4.1 Market Definition 17

4.2 Market Drivers 18

4.2.1 Increasing prevalence of chronic diseases 18

4.2.2 Growing geriatric population 19

4.2.3 Rising initiatives by various government associations 20

4.3 Impact Analysis of Market Drivers 21

4.4 Market Restraints 21

4.4.1 High costs of biological drugs 21

4.4.2 Patent expiration of various blockbuster biological drugs 22

4.4.3 Risk of adverse effects associated with biological injectable medicines 22

4.5 Impact analysis of Market Restraints 23

4.6 Opportunities 24

4.6.1 Advancements in biomedical science 24

4.7 Market Trends 24

4.7.1 VEGF therapy is gaining popularity in the biopharmaceutical industry 24

4.7.2 GMOs are gaining importance in the biological drugs market 25

Chapter 5 Global Market Size And Forecast 26

Chapter 6 Market Size and Forecast by Therapeutic Protein 30

6.1 Enbrel 30

6.2 Lantus 33

6.3 Neulasta 35

6.4 Avonex 37

6.5 NovoLog 40

6.6 Rebif 42

6.7 Humalog 44

6.8 Aranesp 46

6.9 Epogen 48

6.10 Levemir 50

6.11 Victoza 52

6.12 Betaseron 54

6.13 Neupogen 56

6.14 Eylea 58

Chapter 7 Market Size and Forecast by mAb 60

7.1 Humira 60

7.2 Remicade 63

7.3 Rituxan 65

7.4 Avastin 67

7.5 Herceptin 70

7.6 Lucentis 72

Chapter 8 Market Size and Forecast by Vaccine 74

8.1 Prenvar 13 74

8.2 Gardasil 77

8.3 Fluzone 79

8.4 Varivax 81

8.5 Cervarix 83

Chapter 9 Market Size and Forecast by Geography 85

9.1 North America 85

9.2 Europe 94

9.3 Asia 103

9.4 Rest of the World (RoW) 112

Chapter 10 Pipeline Biological Drugs 113

10.1 Biological drugs under development for auto-immune diseases 113

10.2 Biological drugs under development for blood diseases 114

10.3 Biological drugs under development for cancer and related conditions 115

10.4 Biological drugs under development for diabetes and cardiovascular diseases 116

Chapter 11 Competitive Scenario 117

11.1 Competitive Benchmarking 117

Chapter 12 Company Profiles 118

12.1 Pfizer Inc. 118

12.1.1 Company Overview 118

12.1.2 Product and Services 119

12.1.3 Financial Performance 119

12.1.4 Recent Developments 120

12.2 Abbott Laboratories 122

12.2.1 Company Overview 122

12.2.2 Product and Services 123

12.2.3 Financial Performance 124

12.2.4 Recent Developments 124

12.3 Novartis AG 125

12.3.1 Company Overview 125

12.3.2 Product and Services 126

12.3.3 Financial Performance 127

12.3.4 Recent Developments 127

12.4 Eli Lilly and Company 129

12.4.1 Company Overview 129

12.4.2 Product and Services 129

12.4.3 Financial Performance 130

12.4.4 Recent Developments 130

12.5 GlaxoSmithKline plc. 131

12.5.1 Company Overview 131

12.5.2 Product and Services 131

12.5.3 Financial Performance 132

12.5.4 Recent Developments 132

12.6 Bristol-Myers Squibb Company 135

12.6.1 Company Overview 135

12.6.2 Product and Services 135

12.6.3 Financial Performance 136

12.6.4 Recent Developments 136

12.7 Merck and Co., Inc. 139

12.7.1 Company Overview 139

12.7.2 Product and Services 139

12.7.3 Financial Performance 140

12.7.4 Recent Developments 140

12.8 Amgen Inc. 142

12.8.1 Company Overview 142

12.8.2 Product and Services 142

12.8.3 Financial Performance 143

12.8.4 Recent Developments 143

12.9 Baxter International Inc. 145

12.9.1 Company Overview 145

12.9.2 Product and Services 145

12.9.3 Financial Performance 146

12.9.4 Recent Developments 146

12.10 Biogen Idec 149

12.10.1 Company Overview 149

12.10.2 Product and Services 149

12.10.3 Financial Performance 150

12.10.4 Recent Developments 150

List of Tables

TABLE 1 Market snapshot: Global market for biological drugs (2014 and 2020) 13

TABLE 2 Major biological drugs and their applications 19

TABLE 3 Drivers for global biological drugs market: Impact analysis 21

TABLE 4 Major biological drugs and their adverse effects 23

TABLE 5 Restraints for global biological drugs market: Impact analysis 23

TABLE 6 Global market for biological drugs, by geography, 2009-2013 (US$ Mn) 26

TABLE 7 Global market for biological drugs, by geography, 2014-2020 (US$ Mn) 27

TABLE 8 Global market for biological drugs, by segment, 2009-2013 (US$ Mn) 28

TABLE 9 Global market for biological drugs, by segment, 2014-2020 (US$ Mn) 29

TABLE 10 Global market for Enbrel, by geography, 2009-2013 (US$ Mn) 31

TABLE 11 Global market for Enbrel, by geography, 2014-2020 (US$ Mn) 31

TABLE 12 Global market for Lantus, by geography, 2009-2013 (US$ Mn) 33

TABLE 13 Global market for Lantus, by geography, 2014-2020 (US$ Mn) 34

TABLE 14 Global market for Neulasta, by geography, 2009-2013 (US$ Mn) 35

TABLE 15 Global market for Neulasta, by geography, 2014-2020 (US$ Mn) 36

TABLE 16 Global market for Avonex, by geography, 2009-2013 (US$ Mn) 38

TABLE 17 Global market for Avonex, by geography, 2014-2020 (US$ Mn) 38

TABLE 18 Global market for NovoLog, by geography, 2009-2013 (US$ Mn) 40

TABLE 19 Global market for NovoLog, by geography, 2014-2020 (US$ Mn) 41

TABLE 20 Global market for Rebif, by geography, 2009-2013 (US$ Mn) 42

TABLE 21 Global market for Rebif, by geography, 2014-2020 (US$ Mn) 43

TABLE 22 Global market for Humalog, by geography, 2009-2013 (US$ Mn) 44

TABLE 23 Global market for Humalog, by geography, 2014-2020 (US$ Mn) 45

TABLE 24 Global market for Aranesp, by geography, 2009-2013 (US$ Mn) 46

TABLE 25 Global market for Aranesp, by geography, 2014-2020 (US$ Mn) 47

TABLE 26 Global market for Epogen, by geography, 2009-2013 (US$ Mn) 48

TABLE 27 Global market for Epogen, by geography, 2014-2020 (US$ Mn) 49

TABLE 28 Global market for Levemir, by geography, 2009-2013 (US$ Mn) 50

TABLE 29 Global market for Levemir, by geography, 2014-2020 (US$ Mn) 51

TABLE 30 Global market for Victoza, by geography, 2009-2013 (US$ Mn) 52

TABLE 31 Global market for Victoza, by geography, 2014-2020 (US$ Mn) 53

TABLE 32 Global market for Betaseron, by geography, 2009-2013 (US$ Mn) 54

TABLE 33 Global market for Betaseron, by geography, 2014-2020 (US$ Mn) 55

TABLE 34 Global market for Neupogen, by geography, 2009-2013 (US$ Mn) 56

TABLE 35 Global market for Neupogen, by geography, 2014-2020 (US$ Mn) 57

TABLE 36 Global market for Eylea, by geography, 2009-2013 (US$ Mn) 58

TABLE 37 Global market for Eylea, by geography, 2014-2020 (US$ Mn) 59

TABLE 38 Global market for Humira, by geography, 2009-2013 (US$ Mn) 61

TABLE 39 Global market for Humira, by geography, 2014-2020 (US$ Mn) 61

TABLE 40 Global market for Remicade, by geography, 2009-2013 (US$ Mn) 63

TABLE 41 Global market for Remicade, by geography, 2014-2020 (US$ Mn) 64

TABLE 42 Global market for Rituxan, by geography, 2009-2013 (US$ Mn) 65

TABLE 43 Global market for Rituxan, by geography, 2014-2020 (US$ Mn) 66

TABLE 44 Global market for Avastin, by geography, 2009-2013 (US$ Mn) 68

TABLE 45 Global market for Avastin, by geography, 2014-2020 (US$ Mn) 68

TABLE 46 Global market for Herceptin, by geography, 2009-2013 (US$ Mn) 70

TABLE 47 Global market for Herceptin, by geography, 2014-2020 (US$ Mn) 71

TABLE 48 Global market for Lucentis, by geography, 2009-2013 (US$ Mn) 72

TABLE 49 Global market for Lucentis, by geography, 2014-2020 (US$ Mn) 73

TABLE 50 Global market for Prevnar 13, by geography, 2009-2013 (US$ Mn) 75

TABLE 51 Global market for Prevnar 13, by geography, 2014-2020 (US$ Mn) 75

TABLE 52 Global market for Gardasil, by geography, 2009-2013 (US$ Mn) 77

TABLE 53 Global market for Gardasil, by geography, 2014-2020 (US$ Mn) 78

TABLE 54 Global market for Fluzone, by geography, 2009-2013 (US$ Mn) 79

TABLE 55 Global market for Fluzone, by geography, 2014-2020 (US$ Mn) 80

TABLE 56 Global market for Varivax, by geography, 2009-2013 (US$ Mn) 81

TABLE 57 Global market for Varivax, by geography, 2014-2020 (US$ Mn) 82

TABLE 58 Global market for Cervarix, by geography, 2009-2013 (US$ Mn) 83

TABLE 59 Global market for Cervarix, by geography, 2014-2020 (US$ Mn) 84

TABLE 60 North America market for biological drugs, by country, 2009-2013 (US$ Mn) 86

TABLE 61 North America market for biological drugs, by country, 2014-2020 (US$ Mn) 87

TABLE 62 North America market for biological drugs, by therapeutic protein, 2009-2013 (US$ Mn) 88

TABLE 63 North America market for biological drugs, by therapeutic protein, 2014-2020 (US$ Mn) 89

TABLE 64 North America market for biological drugs, by mAb, 2009-2013 (US$ Mn) 90

TABLE 65 North America market for biological drugs, by mAb, 2014-2020 (US$ Mn) 91

TABLE 66 North America market for biological drugs, by vaccine, 2009-2013 (US$ Mn) 92

TABLE 67 North America market for biological drugs, by vaccine, 2014-2020 (US$ Mn) 93

TABLE 68 Europe market for biological drugs, by country, 2009-2013 (US$ Mn) 95

TABLE 69 Europe market for biological drugs, by country, 2014-2020 (US$ Mn) 95

TABLE 70 Europe market for biological drugs, by therapeutic protein, 2009-2013 (US$ Mn) 97

TABLE 71 Europe market for biological drugs, by therapeutic protein, 2014-2020 (US$ Mn) 98

TABLE 72 Europe market for biological drugs, by mAb, 2009-2013 (US$ Mn) 99

TABLE 73 Europe market for biological drugs, by mAb, 2014-2020 (US$ Mn) 100

TABLE 74 Europe market for biological drugs, by vaccine, 2009-2013 (US$ Mn) 101

TABLE 75 Europe market for biological drugs, by vaccine, 2014-2020 (US$ Mn) 102

TABLE 76 Asia market for biological drugs, by country, 2009-2013 (US$ Mn) 104

TABLE 77 Asia market for biological drugs, by country, 2014-2020 (US$ Mn) 104

TABLE 78 Asia market for biological drugs, by therapeutic protein, 2009-2013 (US$ Mn) 106

TABLE 79 Asia market for biological drugs, by therapeutic protein, 2014-2020 (US$ Mn) 107

TABLE 80 Asia market for biological drugs, by mAb, 2009-2013 (US$ Mn) 108

TABLE 81 Asia market for biological drugs, by mAb, 2014-2020 (US$ Mn) 109

TABLE 82 Asia market for biological drugs, by vaccine, 2009-2013 (US$ Mn) 110

TABLE 83 Asia market for biological drugs, by vaccine, 2014-2020 (US$ Mn) 111

TABLE 84 Some pipeline biological drugs for auto-immune diseases 113

TABLE 85 Some pipeline biological drugs for blood diseases 114

TABLE 86 Some pipeline biological drugs for cancer and related conditions 115

TABLE 87 Some pipeline biological drugs for diabetes and cardiovascular diseases 116

TABLE 88 Pfizer major product segments 119

TABLE 89 Abbott major product categories 123

TABLE 90 Novartis product segments 126

TABLE 91 Lilly product segments 129

TABLE 92 GlaxoSmithKline product segments 131

TABLE 93 Bristol-Myers Squibb key product and brands 135

TABLE 94 Merck key product categories 139

TABLE 95 Amgen product category 142

TABLE 96 Baxter major product categories 145

TABLE 97 Biogen Idec major therapies and their uses 149

List of Figures

FIG. 1 Biological drugs market: Porter's five force analysis 14

FIG. 2 Biological drugs market, by therapeutic proteins, mAbs and vaccine 18

FIG. 3 Geriatric population in major countries, 2000-2050, (% share) 20

FIG. 4 Global market for biological drugs by geography 2013 (% share) 26

FIG. 5 Global market for biological drugs by segment 2013 (% share) 28

FIG. 6 Global market for Enbrel by geography 2013 (% share) 30

FIG. 7 Global market for Lantus by geography 2013 (% share) 33

FIG. 8 Global market for Neulasta by geography 2013 (% share) 35

FIG. 9 Global market for Avonex by geography 2013 (% share) 37

FIG. 10 Global market for NovoLog by geography 2013 (% share) 40

FIG. 11 Global market for Rebif by geography 2013 (% share) 42

FIG. 12 Global market for Humalog by geography 2013 (% share) 44

FIG. 13 Global market for Aranesp by geography 2013 (% share) 46

FIG. 14 Global market for Epogen by geography 2013 (% share) 48

FIG. 15 Global market for Levemir by geography 2013 (% share) 50

FIG. 16 Global market for Victoza by geography 2013 (% share) 52

FIG. 17 Global market for Betaseron by geography 2013 (% share) 54

FIG. 18 Global market for Neupogen by geography 2013 (% share) 56

FIG. 19 Global market for Eylea by geography 2013 (% share) 58

FIG. 20 Global market for Humira by geography 2013 (% share) 60

FIG. 21 Global market for Remicade by geography 2013 (% share) 63

FIG. 22 Global market for Rituxan by geography 2013 (% share) 65

FIG. 23 Global market for Avastin by geography 2013 (% share) 67

FIG. 24 Global market for Herceptin by geography 2013 (% share) 70

FIG. 25 Global market for Lucentis by geography 2013 (% share) 72

FIG. 26 Global market for Prevnar 13 by geography 2013 (% share) 74

FIG. 27 Global market for Gardasil by geography 2013 (% share) 77

FIG. 28 Global market for Fluzone by geography 2013 (% share) 79

FIG. 29 Global market for Varivax by geography 2013 (% share) 81

FIG. 30 Global market for Cervarix by geography 2013 (% share) 83

FIG. 31 North America market for biological drugs, by country, 2013 (% share) 86

FIG. 32 North America market for biological drugs, by therapeutic protein, 2013 (% share) 87

FIG. 33 North America market for biological drugs, by mAb, 2013 (% share) 90

FIG. 34 North America market for biological drugs, by vaccine, 2013 (% share) 92

FIG. 35 Europe market for biological drugs, by country, 2013 (% share) 94

FIG. 36 Europe market for biological drugs, by therapeutic protein, 2013 (% share) 96

FIG. 37 Europe market for biological drugs, by mAb, 2013 (% share) 99

FIG. 38 Europe market for biological drugs, by vaccine, 2013 (% share) 101

FIG. 39 Asia market for biological drugs, by country, 2013 (% share) 103

FIG. 40 Asia market for biological drugs, by therapeutic protein, 2013 (% share) 105

FIG. 41 Asia market for biological drugs, by mAb, 2013 (% share) 108

FIG. 42 Asia market for biological drugs, by vaccine, 2013 (% share) 110

FIG. 43 Competitive landscape of biological drugs market 117

FIG. 44 Pfizer revenue and net income, 2011-2013 (US$ Mn) 119

FIG. 45 Abbott net sales and net earnings, 2011-2013 (US$ Mn) 124

FIG. 46 Novartis net sales and net income, 2011-2013 (US$ Mn) 127

FIG. 47 Lilly revenue and net income, 2011-2013 (US$ Mn) 130

FIG. 48 GlaxoSmithKline turnover and profit, 2011-2013 (US$ Mn) 132

FIG. 49 Bristol-Myers Squibb revenue and net earnings, 2011-2013 (US$ Mn) 136

FIG. 50 Merck sales and net income, 2011-2013 (US$ Mn) 140

FIG. 51 Amgen revenue and net income, 2011-2013 (US$ Mn) 143

FIG. 52 Baxter net sales and net income, 2011-2013 (US$ Mn) 146

FIG. 53 Biogen Idec revenue and net income, 2011-2013 (US$ Mn) 150

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Veterinary vaccines are extensively used in the prevention of life-threatening animal diseases. This report on the global veterinary vaccines market analyzes the current and future prospects of the market. ...

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Human Vaccines Market: Scope and Methodology This report provides in-depth region wise and country wise analysis of the human vaccines market. Stakeholders of this report include manufacturers of human ...

Global Veterinary Vaccines Market

October 2016 $ 4250

Download Unlimited Documents from Trusted Public Sources

The future of the Vaccine Industry in the UK

  • December 2016
    2 pages
  • Vaccine  

    Infectious Dise...  

  • United Kingdom  

View report >

Vaccine Industry in Canada

  • December 2016
    6 pages
  • Vaccine  

  • Canada  

View report >

Influenza Statistics in the US

  • November 2016
    7 pages
  • Influenza  

    Influenza Vacci...  

    Vaccine  

  • United States  

View report >

Global Therapy Market

12 days ago

Global Vaccine Supply

18 days ago

Related Market Segments :

Vaccine

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.